The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first.
Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...
Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a BCMA-directed ...
The compounds have exploded in popularity, but big questions about safety and effectiveness are still unresolved.
Engineers at the University of Pennsylvania and Rice University have refined a technology for editing individual genetic "base pairs" to a new level of precision, opening the door to safer, more ...
Engineers at the University of Pennsylvania and Rice University have refined a technology for editing individual genetic ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
Researchers from New England Biolabs and Yale University have created a system for engineering the first fully synthetic ...
Jeffrey Epstein discussed numerous ideas of genetic superiority in the files, including creating his own “designer babies.” Epstein’s journey marks a darker history and requires action to truly ...
In “What We Inherit,” Sam Trejo and Daphne O. Martschenko examine the link between genetic myths and social genomics.
The first large-scale genetic study of cancer in cats has highlighted the similarity between cancer driver genes in cats and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results